<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020015.anc" start="210" end="221" sStart="-1" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="The protective effects of antibody to pneumococcal capsular polysaccharides have been appreciated since the development of serum therapy, in which passively &lt;b&gt;transferred&lt;/b&gt;, serotype-specific antipneumococcal serum reduced mortality from pneumococcal pneumonia by half [1]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020015.anc" start="16430" end="16441" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="In mice, either passively &lt;b&gt;transferred&lt;/b&gt; human serum IgG against pneumococcal surface protein A or vaccine-induced antibodies to pneumococcal surface protein A and/or pneumolysin are protective against invasive disease." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="1506" end="1515" sStart="null" offset="102" sid="r8.suggest.v.0957" wn="1" wnkey="suggest%2:32:00::" annotator="veweser" text="The reason for the decline in incidence has not been conclusively determined, yet it is often suggested that the acquisition of anticapsular antibodies plays a critical role in this decline [6,7]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="21539" end="21546" sStart="null" offset="31" sid="r8.suggest.v.0436" wn="3" wnkey="suggest%2:32:02::" annotator="cgozo" text="In particular, recent analyses suggest that serotypes 1 and 5 have relatively stable incidence over a range of age groups (W." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="14653" end="14659" sStart="null" offset="155" sid="r11.strong.j.0571" wn="1" wnkey="strong%3:00:00::" annotator="vebatchelder" text="As we discuss below, each of these lines of evidence is subject to caveats, but we believe that, taken together, these observations make a strong case for the importance of one or more factors other than acquisition of anticapsular antibodies in the development of protection against pneumococcal disease." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="2876" end="2882" sStart="null" offset="99" sid="r8.state.n.0964" wn="2147483647" wnkey="null" annotator="cgozo" text="Incidence of invasive pneumococcal disease was measured in eight sites around the United States participating in the Centers for Disease Control and Prevention's Active Bacterial Core Surveillance between 1994 and 1999." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="14442" end="14448" sStart="null" offset="113" sid="r8.state.n.0540" wn="2147483647" wnkey="null" annotator="cgozo" text="Moreover, only a slight increase in anticapsular antibody concentration is measurable in Finnish, United States, and Israeli toddlers during the same age range." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="9844" end="9850" sStart="null" offset="95" sid="r8.state.n.0104" wn="2147483647" wnkey="null" annotator="cgozo" text="A recent publication describes the age-specific proportion of children in the United States with anti-type-14 polysaccharide antibody concentration exceeding the putative protective concentration of 0.2 ?g/ml (Figure 3 of [9])." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="16896" end="16902" sStart="null" offset="2" sid="r8.number.n.0984" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="A number of investigators have tested the hypothesis that antibodies to the pneumococcal teichoic acid, known as cell wall polysaccharide (CWPS), are capable of protecting individuals against pneumococcal invasive disease." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="17511" end="17517" sStart="null" offset="48" sid="r8.number.n.0132" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="Notably, such antibodies might be elicited by a number of bacteria in addition to pneumococci, such as Haemophilus influenzae, which also produce phosphorylcholine." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="1280" end="1284" sStart="null" offset="239" sid="r8.life.n.0421" wn="4" wnkey="life%1:26:00::" annotator="veweser" text="In unimmunized populations, the incidence of invasive disease follows a well-known age distribution, peaking in the first 2 y of life, declining by more than an order of magnitude by the second and third decades of life, and then rising at an accelerating pace, with incidence in persons over 70 y approaching that in infants [5]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="22442" end="22448" sStart="null" offset="124" sid="r9.level.n.0469" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="With respect to the absolute timing of protection relative to the acquisition of antibody, one could argue that low levels of anticapsular antibody, perhaps of low affinity, may be present and even active at levels below those that can be reliably detected by current assays, or that B cell memory may be present and protective at an earlier age than that at which high levels of antibody are measurable." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="16369" end="16375" sStart="null" offset="333" sid="r9.level.n.0991" wn="1" wnkey="level%1:07:00::" annotator="cgozo" text="In Kenya, antibodies to another conserved protein, pneumococcal surface adhesin A, showed similar distributions in the first, second, and subsequent years of life, while in Finland, levels of these antibodies were already high (equivalent to adult levels) in the first year of life, and increased above these levels in the second year." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="11728" end="11734" sStart="null" offset="97" sid="r9.level.n.0367" wn="1" wnkey="level%1:07:00::" annotator="cgozo" text="These data are broadly consistent with those published for the United States; antibody levels rise very gradually, though detectably, during the second and third years of life." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="18304" end="18310" sStart="null" offset="77" sid="r9.kill.v.0510" wn="2147483645" wnkey="null" annotator="anfahmy" text="We have also shown that intranasal immunization with unencapsulated, killed pneumococci protects against nasopharyngeal colonization, in a fashion that is independent of antibody but requires CD4+ T cells at the time of challenge." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020015.anc" start="16274" end="16278" sStart="null" offset="238" sid="r10.high.j.0973" wn="1" wnkey="high%3:00:02::" annotator="veweser" text="In Kenya, antibodies to another conserved protein, pneumococcal surface adhesin A, showed similar distributions in the first, second, and subsequent years of life, while in Finland, levels of these antibodies were already high (equivalent to adult levels) in the first year of life, and increased above these levels in the second year." />
  </sentences>
</list>